Treating Clostridioides difficile: Could Microbiota-based Live Biotherapeutic Products Provide the Answer?

被引:8
作者
Nagarakanti, Sandhya [1 ,2 ]
Orenstein, Robert [1 ]
机构
[1] Mayo Clin Arizona, Div Infect Dis, Phoenix, AZ USA
[2] Mayo Clin Arizona, Div Infect Dis, 577 East Mayo Blvd, Phoenix, AZ 85054 USA
来源
INFECTION AND DRUG RESISTANCE | 2023年 / 16卷
关键词
Clostridioides difficile; microbiome; live biotherapeutic products; recurrence; INFECTION; RECURRENT; METABOLITES; SER-109;
D O I
10.2147/IDR.S400570
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Clostridioides difficile infection (CDI) is a pressing health care issue due to the limited effectiveness of current treatments and high recurrence rates. Current available antibiotic options for CDI disrupt the fecal microbiome which predisposes recurrent CDI. Fecal microbiota transplantation (FMT) has improved the outcomes of recurrent CDI, but concerns surrounding the safety and standardization of the product persist. Microbiota-based live biotherapeutic products (LBPs), are emerging as potential alternatives to FMT for CDI treatment. This review explores the potential of LBPs as safe and effective therapy for CDI. While preclinical and early clinical studies have shown promising results, further research is necessary to determine the optimal composition and dosage of LBPs and to ensure their safety and efficacy in clinical practice. Overall, LBPs hold great promise as a novel therapy for CDI and warrant further investigation in other conditions related to disruption of the colonic microbiota.
引用
收藏
页码:3137 / 3143
页数:7
相关论文
共 43 条
  • [21] Development of live biotherapeutic products: a position statement of Asia-Pacific Microbiota Consortium
    Tseng, Ching-Hung
    Wong, Sunny
    Yu, Jun
    Lee, Yeong Yeh
    Terauchi, Jun
    Lai, Hsin-Chih
    Luo, Jiing-Chyuan
    Kao, Cheng Yen
    Yu, Sung-Liang
    Liou, Jyh-Ming
    Wu, Deng-Chyang
    Hou, Ming-Chih
    Wu, Ming-Shiang
    Wu, Jiunn-Jong
    Sung, Joseph J. Y.
    El-Omar, Emad M.
    Wu, Chun-Ying
    GUT, 2025, : 706 - 713
  • [22] Fecal Microbiota, Live-js']jslm (RBL; REBYOTA™) for Recurrent Clostridioides difficile Infection
    Garcia, Mary
    Castex, Julie
    Duhaime, Erin
    Monk, Miranda
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2024, 20 (10):
  • [23] Fecal Microbiota-based Therapeutics for Recurrent Clostridium difficile Infection, Ulcerative Colitis and Obesity
    Carlucci, Christian
    Petrof, Elaine O.
    Allen-Vercoe, Emma
    EBIOMEDICINE, 2016, 13 : 37 - 45
  • [24] Practical use of fecal microbiota spores, live-brpk (formerly SER-109): an oral therapeutic for the prevention of recurrent Clostridioides difficile infection
    Rosenberg, Jonathan
    Ritter, Timothy
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2023,
  • [25] Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US
    Thomas Lodise
    Amy Guo
    Min Yang
    Erin E. Cook
    Wei Song
    Danni Yang
    Qingyuan Wang
    Angela Zhao
    Markian Bochan
    Advances in Therapy, 2023, 40 : 2801 - 2819
  • [26] Fecal Microbiota Transplantation May Be the Best Option in Treating Multiple Clostridioides difficile Infection: A Network Meta-Analysis
    Fanni Dembrovszky
    Noémi Gede
    Zsolt Szakács
    Péter Hegyi
    Szabolcs Kiss
    Nelli Farkas
    Zsolt Molnár
    Marcell Imrei
    Dóra Dohos
    Zoltán Péterfi
    Infectious Diseases and Therapy, 2021, 10 : 201 - 211
  • [27] Retrospective Analysis of the Safety and Efficacy of Fecal Microbiota, Live-js']jslm (REBYOTA™) Administered Under Enforcement Discretion to Patients With Clostridioides difficile Infection
    Feuerstadt, Paul
    Harvey, Adam
    Yoho, David S.
    Garcia-Diaz, Julia B.
    Knapple, Whitfield L.
    Bancke, Lindy
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (05):
  • [28] Efficacy and Practical Implementation of Fecal Microbiota Spores, Live-BRPK: A Novel Approach for Preventing Recurrent Clostridioides difficile Infection
    Feuerstadt, Paul
    LaPlante, Kerry L.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (1S) : S22 - S26
  • [29] Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection
    Dubberke, Erik R.
    Orenstein, Robert
    Khanna, Sahil
    Guthmueller, Beth
    Lee, Christine
    INFECTIOUS DISEASES AND THERAPY, 2023, 12 (02) : 703 - 709
  • [30] Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA
    Thomas Lodise
    Amy Guo
    Min Yang
    Erin E. Cook
    Wei Song
    Danni Yang
    Qingyuan Wang
    Angela Zhao
    Markian Bochan
    Advances in Therapy, 2023, 40 : 2784 - 2800